Furiex Pharmaceuticals, Inc. (FURX):企業概要、財務及び戦略的SWOT分析

◆英語タイトル:Furiex Pharmaceuticals, Inc. (FURX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH259182FSA
◆発行会社(調査会社):GlobalData
◆発行日:2015年1月9日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD300 ⇒換算¥33,300見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD600 ⇒換算¥66,600見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD900 ⇒換算¥99,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

Furiex Pharmaceuticals, Inc. (Furiex) is a drug development company. The company develops and markets drug candidates. Its products include nesina, oseni and liovel, kazano, eluxadoline, priligy, novel fluoroquinolone JNJ-Q2, and SYR-472 trelagliptin. The company’s nesina is an oral drug used for the treatment of type 2 diabetes; priligy is used for premature ejaculation; oseni and liovel is a tablet for the treatment of type 2 diabetes. Furiex’s kazano is a single tablet developed from nesina and metformin for the treatment of type 2 diabetes and JNJ-Q2 is an oral formulation for acute bacterial skin and skin-structure infections. It markets products in the US and Europe. Furiex is headquartered in Morrisville, North Carolina, the US.

Furiex Pharmaceuticals, Inc. Key Recent Developments

Nov 05, 2013: Furiex Reports Third Quarter 2013 Financial Results
Oct 28, 2013: Furiex Pharmaceuticals Announces Management Changes
Oct 03, 2013: Furiex Pharmaceuticals Announces Third Quarter 2013 Earnings Release and Conference Call
Aug 06, 2013: Furiex Reports Second Quarter 2013 Financial Results
Jun 28, 2013: Furiex Pharmaceuticals Announces Second Quarter 2013 Earnings Release and Conference Call

This comprehensive SWOT profile of Furiex Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Furiex Pharmaceuticals, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Furiex Pharmaceuticals, Inc. – Key Information
Furiex Pharmaceuticals, Inc. – Overview
Furiex Pharmaceuticals, Inc. – Key Employees
Furiex Pharmaceuticals, Inc. – Key Employee Biographies
Furiex Pharmaceuticals, Inc. – Key Operational Heads
Furiex Pharmaceuticals, Inc. – Major Products and Services
Furiex Pharmaceuticals, Inc. – History
Furiex Pharmaceuticals, Inc. – Company Statement
Furiex Pharmaceuticals, Inc. – Locations And Subsidiaries
Furiex Pharmaceuticals, Inc. – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Furiex Pharmaceuticals, Inc. – Business Description
Furiex Pharmaceuticals, Inc. – Corporate Strategy
Furiex Pharmaceuticals, Inc. – SWOT Analysis
SWOT Analysis – Overview
Furiex Pharmaceuticals, Inc. – Strengths
Furiex Pharmaceuticals, Inc. – Weaknesses
Furiex Pharmaceuticals, Inc. – Opportunities
Furiex Pharmaceuticals, Inc. – Threats
Furiex Pharmaceuticals, Inc. – Key Competitors

Section 3 – Company Financial Performance Charts

Furiex Pharmaceuticals, Inc. – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Furiex Pharmaceuticals, Inc., Key Information
Furiex Pharmaceuticals, Inc., Key Ratios
Furiex Pharmaceuticals, Inc., Share Data
Furiex Pharmaceuticals, Inc., Major Products and Services
Furiex Pharmaceuticals, Inc., History
Furiex Pharmaceuticals, Inc., Key Employees
Furiex Pharmaceuticals, Inc., Key Employee Biographies
Furiex Pharmaceuticals, Inc., Key Operational Heads
Furiex Pharmaceuticals, Inc., Other Locations
Furiex Pharmaceuticals, Inc., Subsidiaries
Furiex Pharmaceuticals, Inc., Key Manufacturing facilities
Furiex Pharmaceuticals, Inc., Key Competitors
Furiex Pharmaceuticals, Inc., SWOT Analysis
Furiex Pharmaceuticals, Inc., Ratios based on current share price
Furiex Pharmaceuticals, Inc., Annual Ratios
Furiex Pharmaceuticals, Inc., Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Furiex Pharmaceuticals, Inc., Performance Chart
Furiex Pharmaceuticals, Inc., Ratio Charts

★海外企業調査レポート[Furiex Pharmaceuticals, Inc. (FURX):企業概要、財務及び戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AFFiRiS AG-製薬・医療分野:企業M&A・提携分析
    Summary Affiris AG (AFFiRiS) is a drug development company that develops and manufactures novel synthetic vaccines against chronic diseases. The company develops customized peptide vaccines based on its proprietary affitome technology for the prevention of Alzheimer's disease, Parkinson's disease, a …
  • NanoViricides, Inc. (NNVC):企業概要、財務及び戦略的SWOT分析
    Summary NanoViricides, Inc. (NanoViricides) is a biopharmaceutical company. The company discovers, develops, and commercializes therapeutics for life-threatening viral infections. Its drug candidates include injectable flucide clinical candidate, oral flucide clinical candidate, EKC-cide-I, hivcide- …
  • Endo International PLC (formerly Endo Health Solutions, Inc.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Endo International PLC (formerl …
  • Kaketsuken K.K.(製薬・医療分野):企業M&A動向
    Summary Kaketsuken K.K. (Kaketsuken) is a pharmaceutical company. The company carries out research, development, manufacturing and supply of vaccines and toxoids, antitoxins, antitumor drug and blood plasma products. It manufactures human and veterinary vaccines such as influenza, Japanese encephali …
  • Renesas Electronics Corporation:企業の戦略・SWOT・財務分析
    Renesas Electronics Corporation - Strategy, SWOT and Corporate Finance Report Summary Renesas Electronics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Ono Pharmaceutical Co., Ltd.:企業のM&A・提携・投資分析
    Ono Pharmaceutical Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ono Pharmaceutical Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • RPS Group Plc:企業のM&A・提携・投資分析
    RPS Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's RPS Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • TV Asahi Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' TV Asahi Corporation Mergers an …
  • Sandoz International GmbH:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sandoz International GmbH Merge …
  • Antero Resources Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Antero Resources Corporation Me …
  • BT Group plc:企業の戦略・SWOT・財務分析
    SummaryBT Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - …
  • Valence Health-製薬・医療分野:企業M&A・提携分析
    Summary Valence Health is a healthcare company that provides healthcare services. The company offers solutions such as consulting, vision platform, quality measurement, cost and utilization, data collection, contract administration, managed services, and actuarial services. It provides health care s …
  • Pon Holdings B.V.:企業の戦略・SWOT・財務分析
    SummaryPon Holdings B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • Addex Therapeutics Ltd (ADXN):企業のM&A・提携動向(医療分野)
    Summary Addex Therapeutics Ltd (Addex) is a biopharmaceutical company. It focuses on the development of orally available, small molecule allosteric modulators for neurological disorders. Addex's product pipeline consists of its lead products, dipraglurant (mGluR5 negative allosteric modulator) to tr …
  • Aer Lingus Group plcの企業概要及び財務/SWOT分析
    Aer Lingus Group plc Fundamental Company Report provides a complete overview of the company’s affairs. The report includes financial and SWOT information, industry analysis, opinions, estimates, Aer Lingus Group plc annual and quarterly forecasts made by stock market experts. The report also enables …
  • National Institute of Agricultural Research-製薬・医療分野:企業M&A・提携分析
    Summary National Institute of Agricultural Research (INRA) is a research institute that conducts research in agriculture, food, nutrition and food safety, environment and land management. The institute provides healthcare services by conducting research in infectious diseases. It develops various co …
  • Almedio Inc. (7859):企業財務及び戦略的SWOT分析
    Summary Almedio Inc. (Almedio), formerly A-BEX is an electronic equipment company that designs, develops and manufactures optical media, test tapes and test discs. The company offers products such as insulating materials, test media, creative media, testing and measuring instruments. It provides con …
  • Alanheri NV:企業の戦略・SWOT・財務分析
    SummaryAlanheri NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - …
  • Traphaco Joint Stock Company (TRA):企業の財務及び戦略的SWOT分析
    Summary Traphaco Joint Stock Company (Traphaco) is a pharmaceutical company that manufactures and trades pharmaceutical products, chemicals, functional food, cosmetic products and other medical equipment and supplies. The company’s pharmaceutical products include analgesics and antispasmodics, antib …
  • Churchill Downs Inc.の企業概要及び財務/SWOT分析
    Churchill Downs Inc. Fundamental Company Report provides a complete overview of the company’s affairs. The report includes financial and SWOT information, industry analysis, opinions, estimates, Churchill Downs Inc. annual and quarterly forecasts made by stock market experts. The report also enables …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆